A new dual drug-device platform demonstrates feasibility and safety for fluorescence-guided resection followed by intraoperative photodynamic therapy in glioblastoma. The report describes an integrated workflow designed to support targeted activation during surgery, addressing a practical limitation of translating photodynamic approaches into real-time operative settings. The case is technical and early, but it matters for neuro-oncology because intraoperative delivery and accurate targeting are often the bottlenecks for PDT integration. By combining surgical guidance with photo-activation steps, the platform aims to reduce uncertainty about where and when therapy is applied. If replicated in larger cohorts, the approach could influence how investigators design interventional trials that require coordination between imaging, device operation, and drug administration. It also sets a framework for building standardized intraoperative timing and safety monitoring. For translational teams, the key deliverable is proof that the combined workflow can be executed without reported major safety issues in a clinical setting.